Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 22,544 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 22,544 shares of the company’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $54.01, for a total transaction of $1,217,601.44. Following the completion of the sale, the chief executive officer owned 431,904 shares in the company, valued at $23,327,135.04. This represents a 4.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 1.5%

KNSA stock traded up $0.79 during mid-day trading on Thursday, reaching $53.78. 861,409 shares of the company traded hands, compared to its average volume of 707,651. The stock has a market cap of $4.12 billion, a price-to-earnings ratio of 72.68 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $54.31. The firm’s 50 day moving average price is $46.26 and its 200 day moving average price is $43.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $207.12 million. During the same period in the prior year, the business posted $0.11 earnings per share. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Inspire Investing LLC purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $1,698,000. Cannon Global Investment Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $530,000. SG Americas Securities LLC boosted its holdings in Kiniksa Pharmaceuticals International by 18.2% during the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock worth $30,825,000 after purchasing an additional 98,783 shares during the last quarter. Virtu Financial LLC purchased a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $267,000. Finally, Invesco Ltd. boosted its holdings in Kiniksa Pharmaceuticals International by 25.9% during the fourth quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock worth $1,334,000 after purchasing an additional 6,656 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and raised guidance — Kiniksa reported EPS and revenue above Street estimates and lifted FY‑2026 revenue guidance, signaling stronger near‑term growth driven by ARCALYST. Earnings & Guidance Release
• Positive Sentiment: Multiple analyst price‑target increases — brokers have raised targets (examples: Canaccord to $64, Citigroup to $60, Wedbush to $59, Wells Fargo to $57), reflecting upgraded revenue/earnings assumptions and supporting buy‑side interest. Canaccord Note More Analyst Notes
• Positive Sentiment: Product momentum and pipeline — management increased ARCALYST expectations after strong net product revenue, and KPL‑387 Phase 2 readout (recurrent pericarditis) and a planned Phase 3 could be meaningful catalysts later in 2026. Pipeline Release
• Positive Sentiment: Market sentiment lift — media coverage notes improved investor sentiment following the “healthcare surprise,” drawing renewed interest in the stock. Kalkine Media
• Neutral Sentiment: Earnings materials available — slide deck and call transcript provide detail on channel dynamics and assumptions; useful for validating management’s guidance and margin outlook. Earnings Presentation
• Negative Sentiment: Insider sale — Director Barry D. Quart sold 13,099 shares under a pre‑arranged Rule 10b5‑1 plan, cutting his stake ~51%; while planned, such selling can create short‑term sentiment pressure. SEC Filing

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent analyst reports. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Friday, April 17th. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Finally, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.